Moffitt logo

Choose a type to search within:

All Doctors Clinical Trials Researchers
search icon
Call Today
1-888-663-3488

Clinical Trials Search

Back to Search Results

Clinical Trial 19715

Cancer Type: Malignant Hematology
Interventions:Bendamustine (); Mosunetuzumab (); Polatuzumab Vedotin (); Rituxan (rituximab); Tocilizumab (); rituximab ()

Study Type: Treatment
Phase of Study: Phase I/II
Investigators:

  • Julio Chavez

Call 813-745-6100
or 1-800-679-0775
Overview

Study Title

An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Mosunetuzumab (Btct4465a) In Combination With Polatuzumab Vedotin In Patients With B-Cell Non-Hodgkin Lymphoma

Summary

This study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of mosunetuzumab in combination with polatuzumab vedotin in participants with B-cell non-Hodgkin lymphoma (NHL). It will consist of a dose finding portion and two randomized cohorts for participants with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL).

Objective

Safety Endpoints To evaluate the safety and tolerability of mosunetuzumab plus polatuzumab vedotin in patients with R/R DLBCL or FL, including estimation of the MTD, determination of the RP2D, and characterization of DLTs Efficacy Objective To make a preliminary assessment of the anti-tumor activity of mosunetuzumab plus polatuzumab vedotin Primary Efficacy Endpoints To evaluate the efficacy of mosunetuzumab plus polatuzumab vedotin compared with polatuzumab vedotin plus bendamustine and rituximab in patients with R/R DLBCL To evaluate the efficacy of mosunetuzumab plus polatuzumab vedotin compared with physicians choice of rituximab plus chemotherapy (CHOP or CVP) or obinutuzumab plus bendamustine followed by obinutuzumab maintenance in patients with R/R FL

Inclusion Criteria

  • ECOG PS of 0, 1, or 2
  • Histologically confirmed FL or DLBCL
  • Must have received at least one prior systemic treatment regimen containing an anti-CD20−directed therapy for DLBCL or FL
  • Relapsed to prior regimen(s) after having a documented history of response (complete response [CR], CR unconfirmed [CRu], or partial response [PR]) of >/= 6 months in duration from completion of regimen(s); or, refractory to any prior regimen, defined as no response to the prior therapy, or progression within 6 months of completion of the last dose of therapy
  • Measurable disease, defined as at least one bi-dimensionally measurable nodal lesion, defined as > 1.5 cm in its longest dimension, or at least one bi-dimensionally measurable extranodal lesion, defined as > 1.0 cm in its longest dimension
  • Adequate hematologic, renal, and hepatic function
  • Additional criteria apply

    • Exclusion Criteria

  • Prior treatment with mosunetuzumab or other CD20-directed bispecific antibodies
  • Prior treatment with polatuzumab vedotin
  • Current > Grade 1 peripheral neuropathy
  • Prior use of any monoclonal antibody, radioimmunoconjugate or antibody-drug conjugate (ADC) within 4 weeks before first dose of study treatment
  • Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to first dose of study treatment
  • Treatment with radiotherapy within 2 weeks prior to the first dose of study treatment
  • Autologous stem-cell transplantation (SCT) within 100 days prior to first study treatment administration
  • :Prior treatment with chimeric antigen receptor T-cell (CAR-T) therapy within 30 days before first study treatment administration
  • Prior allogeneic SCT
  • Prior solid organ transplantation
  • Patients with history of confirmed progressive multifocal leukoencephalopathy (PML)
  • Current or past history of central nervous system (CNS) lymphoma or CNS disease
  • History of autoimmune disease
  • Addition exclusions apply

    • Back to top

    Search